SpecGx

Discussion in 'Mallinckrodt' started by anonymous, Mar 15, 2017 at 10:14 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Yeah, the chatter about Aurobindo or Intas has really died down from what it was in July.
     

  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    Didn’t you hear? Aurobindo dropped their bid earlier in the week. Intas was never really serious about their offer. Nobody wants to buy this POS division. Expect a shutdown in a year or two, and all the plants will be sold for pennies on the dollar.
     
  4. anonymous

    anonymous Guest

    Not if they can use assets for next best thing: Weed.
     
  5. anonymous

    anonymous Guest

    You may be right. Colorado makes more money on weed than Mallinckrodt will ever make on drugs.I dont bother to tell people where i work anymore,it's not a point of pride anymore.
     
  6. anonymous

    anonymous Guest

    You should be working and not be here.
    Your new employer will FIRE you!
     
  7. anonymous

    anonymous Guest

    Fire plus Weed = Smoke, hmmm
     
  8. anonymous

    anonymous Guest

    So,Aurobindo bought Novartis generics. They strung Mallinckrodt along like a fish on a line, and then just cut them loose. Funny!
     
  9. anonymous

    anonymous Guest


    WOMP WOMP
     
  10. anonymous

    anonymous Guest

    Mallinckrodt gets jilted again. Nobody wants to buy SpecGX. Maybe they’ll wind down Generics in 2019 to avoid any liability lawsuits. API will then be prepped for a sale once Generics closes shop.
     
  11. anonymous

    anonymous Guest

    You stupid whiners. That's how business work.
    Get your head out of your ass.
     
  12. anonymous

    anonymous Guest

    “That’s how business work.”

    Wow, you are almost believable as an English speaker. Keep practicing, you’ll get it right one day!
     
  13. anonymous

    anonymous Guest

    What's next Mark ? Back to continued operations ? Spinoff ? Run it into the ground until nothing is left ?
     
  14. anonymous

    anonymous Guest

    This is the same troll who keeps bitching about whiners and the like.
    This a## hole needs his ass kicked, just guessing but probably some idiot who has never sold
    Second guess and bet, a big pharma ass clown
     
  15. anonymous

    anonymous Guest

    Haha well said. These clowns are weak!
     
  16. anonymous

    anonymous Guest

    You couldn’t fight your way out of a wet paper bag, you maggot slug coward.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    Let’s not lose sight, this is the big question. The “bookkeeping” maneuver to count SpecGX as discontinued operations was too clever by half. Now it comes back to bite them in the butt.

    My prediction: Generics will be discontinued sometime next year. API remains but will be put on the market.
     
  19. anonymous

    anonymous Guest

    exactly. Let’s “discontinue” this business to juice our YOY and QOQ numbers but also think someone will pay us top dollar for a “discontinued” business. Asinine!!!
     
  20. anonymous

    anonymous Guest

    Am I hearing it correctly that there’s talk of a SpecGX spinoff??